Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Saiqiong Cui"'
Autor:
Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance. Resistance mechanisms to ALK TKIs can
Externí odkaz:
https://doaj.org/article/86d94ff29ae34a21991f4c647c2ab4bb
Publikováno v:
Cancer Communications, Vol 41, Iss 2, Pp 183-186 (2021)
Externí odkaz:
https://doaj.org/article/df187147dd3343eabe3c941676b4b969
Publikováno v:
Chinese Journal of Lung Cancer, Vol 23, Iss 12, Pp 1039-1048 (2020)
Background and objective The mortality rate of lung cancer meningeal metastasis is extremely high. Circulating tumor DNA (ctDNA) has been confirmed to be contain the genomic alterations present in tumors and has been used to monitor tumor progression
Externí odkaz:
https://doaj.org/article/e62acd4134f349d28840b7433f0f8ade
Publikováno v:
OncoTargets and Therapy. 16:17-22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa2fac6e107321cb3f95f5c17af7bf47
https://doi.org/10.2147/ott.s391766
https://doi.org/10.2147/ott.s391766
Publikováno v:
OncoTargets and therapy
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is effective in EGFR T790M positive non-small-cell lung cancer (NSCLC). Despite the efficacy of osimertinib, patients inevitably develop resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c0032556cabdd302ad385e657b2ee6
https://doi.org/10.2147/ott.s318250
https://doi.org/10.2147/ott.s318250
Publikováno v:
Cancer Communications
Cancer Communications, Vol 41, Iss 2, Pp 183-186 (2021)
Cancer Communications, Vol 41, Iss 2, Pp 183-186 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6817866daf7761848f0c17cd562f815
http://europepmc.org/articles/PMC7896746
http://europepmc.org/articles/PMC7896746
Objective As a second-generation oral anaplastic lymphoma kinase (ALK) inhibitor, ceritinib was recommended as posterior line therapy in patients with crizotinib resistance or intolerance. While in the real world, the clinical efficacy and safety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::551072facfe511463863451f4983e58f
https://doi.org/10.21203/rs.3.rs-983285/v1
https://doi.org/10.21203/rs.3.rs-983285/v1
